Page last updated: 2024-11-04

vorinostat and Colitis Gravis

vorinostat has been researched along with Colitis Gravis in 2 studies

Vorinostat: A hydroxamic acid and anilide derivative that acts as a HISTONE DEACETYLASE inhibitor. It is used in the treatment of CUTANEOUS T-CELL LYMPHOMA and SEZARY SYNDROME.
vorinostat : A dicarboxylic acid diamide comprising suberic (octanedioic) acid coupled to aniline and hydroxylamine. A histone deacetylase inhibitor, it is marketed under the name Zolinza for the treatment of cutaneous T cell lymphoma (CTCL).

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's2 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Buzza, MS1
Johnson, TA1
Conway, GD1
Martin, EW1
Mukhopadhyay, S1
Shea-Donohue, T1
Antalis, TM1
Rosen, MJ1
Frey, MR1
Washington, MK1
Chaturvedi, R1
Kuhnhein, LA1
Matta, P1
Revetta, FL1
Wilson, KT1
Polk, DB1

Other Studies

2 other studies available for vorinostat and Colitis Gravis

ArticleYear
Inflammatory cytokines down-regulate the barrier-protective prostasin-matriptase proteolytic cascade early in experimental colitis.
    The Journal of biological chemistry, 2017, 06-30, Volume: 292, Issue:26

    Topics: Animals; Colitis, Ulcerative; Colon; Crohn Disease; Dextran Sulfate; Disease Models, Animal; Humans;

2017
STAT6 activation in ulcerative colitis: a new target for prevention of IL-13-induced colon epithelial cell dysfunction.
    Inflammatory bowel diseases, 2011, Volume: 17, Issue:11

    Topics: Apoptosis; Blotting, Western; Case-Control Studies; Cells, Cultured; Child; Claudins; Colitis, Ulcer

2011